17-AAG, an inhibitor of HSP90, suppresses cellular growth of mesothelioma cell lines in vitro

被引：0
|
作者：
Korfee, S.
Gauler, T.
Nishio, K.
Arao, T.
Saijo, N.
Cortes-Incio, D.
Pottgen, C.
Krbek, T.
Seeber, S.
Eberhardt, W. E. E.
机构：
[1] West German Canc Ctr, Essen, Germany
[2] Kinki Univ, Sch Med, Osaka 589, Japan
[3] Natl Canc Ctr Hosp East, Chiba, Japan
[4] Ruhriandklinik, Essen, Germany
来源：
LUNG CANCER | 2006年 / 54卷
关键词：
D O I：
10.1016/S0169-5002(07)70298-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
222
引用
收藏
页码：S54 / S54
页数：1
相关论文
共 50 条
  • [1] Effects of the HSP90 inhibitor 17-AAG in glioblastoma multiforme
    Sauvageot, C.
    Barnes, J.
    Weatherbee, J.
    Ramakrishna, N.
    Kesari, S.
    Stiles, C.
    Kieran, M.
    Wen, P.
    NEURO-ONCOLOGY, 2006, 8 (04) : 417 - 417
  • [2] 17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation
    Y Niikura
    S Ohta
    K J Vandenbeldt
    R Abdulle
    B F McEwen
    K Kitagawa
    Oncogene, 2006, 25 : 4133 - 4146
  • [3] Alleviating neurodegeneration by an anticancer agent - An Hsp90 inhibitor (17-AAG)
    Waza, Masahiro
    Adachi, Hiroaki
    Katsuno, Masahisa
    Minamiyama, Makoto
    Tanaka, Fumiaki
    Sobue, Gen
    INTEGRATED MOLECULAR MEDICINE FOR NEURONAL AND NEOPLASTIC DISORDERS, 2006, 1086 : 21 - 34
  • [4] 17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation
    Niikura, Y.
    Ohta, S.
    Vandenbeldt, K. J.
    Abdulle, R.
    McEwen, B. F.
    Kitagawa, K.
    ONCOGENE, 2006, 25 (30) : 4133 - 4146
  • [5] Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells
    Sauvageot, Claire Marie-Elisabeth
    Weatherbee, Jessica Leigh
    Kesari, Santosh
    Winters, Susan Elizabeth
    Barnes, Jessica
    Dellagatta, Jamie
    Ramakrishna, Naren Raj
    Stiles, Charles Dean
    Kung, Andrew Li-Jen
    Kieran, Mark W.
    Wen, Patrick Yung Chih
    NEURO-ONCOLOGY, 2009, 11 (02) : 109 - 121
  • [6] Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment
    Talaei, Sona
    Mellatyar, Hassan
    Asadi, Asadollah
    Akbarzadeh, Abolfazl
    Sheervalilou, Roghayeh
    Zarghami, Nosratollah
    CHEMICAL BIOLOGY & DRUG DESIGN, 2019, 93 (05) : 760 - 786
  • [7] HSP90 Inhibitor 17-AAG Selectively Eradicates Lymphoma Stem Cells
    Newman, Bryan
    Liu, Yan
    Lee, Hsiu-Fang
    Sun, Duxin
    Wang, Yin
    CANCER RESEARCH, 2012, 72 (17) : 4551 - 4561
  • [8] Acquired resistance to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) in adult and pediatric glioblastoma cell lines
    Gaspar, Nathalie
    Sharp, Swee
    Pacey, Simon
    Jones, Chris
    Walton, Mike
    Vassal, Gilles
    Pearson, Andrew
    Workman, Paul
    NEURO-ONCOLOGY, 2008, 10 (03) : 374 - 374
  • [9] The HSP90 inhibitor 17-AAG improves chemoresistance of cisplatin-resistant esophageal squamous cell carcinoma cell lines
    Ui, Takashi
    Morishima, Kazue
    Saito, Shin
    Sakuma, Yuji
    Fujii, Hirofumi
    Hosoya, Yoshinori
    Yasuda, Yoshikazu
    Niki, Toshiro
    CANCER RESEARCH, 2014, 74 (19)
  • [10] The HSP90 inhibitor 17-AAG potentiates the antileishmanial activity of the ether lipid edelfosine
    Varela-M, Ruben E.
    Mollinedo-Gajate, Cristina
    Muro, Antonio
    Mollinedo, Faustino
    ACTA TROPICA, 2014, 131 : 32 - 36
12345